ReviMo
Robotic mobility assistants enabling individuals with mobility challenges to perform self-care tasks independently.
Website: https://www.revimo.care/
Cover Block
PUBLIC
| Name | ReviMo |
| Tagline | Robotic mobility assistants enabling individuals with mobility challenges to perform self-care tasks independently. |
| Headquarters | Boston, United States |
| Founded | 2022 |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.revimo.care/
- LinkedIn: https://www.linkedin.com/company/revimotion
- AgeTech Collaborative from AARP: https://home.agetechcollaborative.org/startup/network/findacompany/companyprofile?UserKey=
- Heyup Product Listing: https://heyupnow.com/products/niko-mobility-transfer-device
Executive Summary
PUBLIC ReviMo is a Boston-based robotics startup developing the Niko, a smart, compact mobility device designed to enable individuals with significant mobility challenges to perform transfers and self-care tasks independently, a proposition that addresses both a critical patient need and a systemic strain on caregivers and healthcare facilities [ReviMo, retrieved 2024]. Founded in 2022 by Aleksandr Malashchenko, a Babson MBA graduate with a PhD in Mechanical Engineering, the company has gained early validation through participation in the Techstars Physical Health Fort Worth accelerator and the AgeTech Collaborative from AARP [Poets&Quants, Feb 2025] [Techstars Physical Health Fort Worth Announces 11 Companies in Its 2024 Accelerator » Dallas Innovates]. The core product, which uses a remote control and patent-pending seating technology to autonomously approach a bed for a transfer, is positioned as a more flexible and less infrastructure-dependent alternative to traditional ceiling or Hoyer lifts [Disabled Life Alliance, 2023 or later].
While the company's capitalization is not publicly detailed, a pre-seed round was closed in 2022, and third-party estimates model annual revenue at approximately $342,220 with a valuation around $1.1 million, though these figures are unverified [Prospeo] [Revoy - 2026 Funding Rounds & List of Investors - Tracxn]. The business model targets both the home-user market and institutional buyers like nursing homes and hospitals, aiming to reduce caregiver injury risk and operational costs. Over the next 12-18 months, the key milestones to track are the completion of product certification and the launch of commercial production, as stated on the company website, which will serve as the first concrete test of its manufacturing readiness and market acceptance [ReviMo, retrieved 2024].
Data Accuracy: YELLOW -- Core product claims and accelerator participation are well-sourced; founder background is confirmed. Financial metrics and funding details are from single, unverified third-party estimates.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Undisclosed |
Company Overview
PUBLIC
ReviMo was founded in 2022 as a venture-scale robotics startup focused on assistive mobility, originating from the Babson College ecosystem [Poets&Quants, Feb 2025]. The company is headquartered in Boston, Massachusetts, a location that places it within a dense cluster of healthcare and robotics research institutions, including its residency at MassRobotics [David Barsoum - Prev @ ReviMo | Robotics @ Olin..., retrieved 2026]. Founder Aleksandr Malashchenko, an MBA graduate from Babson College with a PhD in Mechanical Engineering, launched the company to address the physical and logistical challenges of patient transfers [B.E.T.A. Challenge Winners Rack Up Double the Awards · Babson Thought & Action, retrieved 2026] [Jennifer DiMartino - Passionate & dedicated..., retrieved 2026].
Key milestones have followed an accelerator-driven path, a common trajectory for early-stage hardware ventures. In 2024, ReviMo was selected for the Techstars Physical Health Fort Worth accelerator program, which typically provides seed funding, mentorship, and network access [Techstars Physical Health Fort Worth Announces 11 Companies in Its 2024 Accelerator » Dallas Innovates]. The company also joined the AgeTech Collaborative from AARP, a program focused on connecting startups with the aging and disability market [AgeTech Collaborative from AARP]. These program participations signal initial industry validation and structured support for navigating the complex healthcare and assistive technology landscape.
The company's public narrative centers on progressing from prototype to production. As of late 2024, ReviMo stated it was in the final stages of launching production and completing certification for its flagship Niko device [ReviMo, retrieved 2024]. This development phase is critical for a hardware company, bridging the gap between demonstration units and commercially viable, regulated products.
Data Accuracy: YELLOW -- Founding details and accelerator participation are confirmed by multiple independent sources; corporate structure and detailed legal entity are not publicly disclosed.
Product and Technology
MIXED ReviMo’s product strategy centers on a single, patent-pending hardware device designed to automate a specific and physically demanding task. The Niko is a compact, robotic mobility assistant that enables individuals with significant mobility challenges to transfer themselves from bed to a chair or commode without requiring a second person [ReviMo, retrieved 2024]. The company positions it as an alternative to traditional ceiling or Hoyer lifts, emphasizing its ability to operate in existing rooms without installed overhead rails and to be summoned by the user via a remote control [Disabled Life Alliance, 2023 or later]. This core functionality is targeted at two distinct customer segments: individual home users seeking greater independence and institutional healthcare facilities aiming to reduce staff injuries during patient transfers [PERPLEXITY SONAR PRO BRIEF].
The device’s technical differentiation rests on its seating technology and autonomous navigation. The patent-pending seating system is intended to facilitate a safe, seated lift [Disabled Life Alliance, 2023 or later]. The robotic base allows the unit to move autonomously to the bedside, perform the transfer, and then transport the user, framing the process as a one-person operation [Danielle Duplin - FreeWind Productions | LinkedIn, retrieved 2026]. While the company’s website and partner listings describe these capabilities, detailed specifications on battery life, weight capacity, or software stack are not publicly available. The company states it is in the final stages of launching production and completing certification, indicating the product is not yet widely commercially deployed [ReviMo, retrieved 2024].
Data Accuracy: YELLOW -- Product claims are consistent across the company website and third-party listings, but technical specifications and certification status are not independently verified.
Market Research
PUBLIC The market for assistive robotics is being reshaped by demographic pressure and a structural shortage of care labor, creating a window for hardware solutions that promise both independence and operational efficiency.
A formal third-party TAM for robotic patient transfer devices is not publicly available, but the underlying demand drivers are well-documented. The U.S. population aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2040, according to the U.S. Census Bureau, increasing the prevalence of mobility limitations [U.S. Census Bureau, 2022]. Concurrently, the healthcare sector faces a persistent shortage of nurses and nursing assistants, with the Bureau of Labor Statistics projecting over 200,000 openings for nursing assistants and orderlies annually through 2032 [BLS, 2023]. These two macro trends create a powerful pull for technologies that reduce the physical burden on caregivers while enabling patient autonomy, a core value proposition for ReviMo's Niko device.
Adjacent and substitute markets provide a useful sizing analog. The global patient lift and sling market, which includes traditional Hoyer lifts and ceiling track systems, was valued at approximately $1.8 billion in 2023 and is forecast to grow at a compound annual rate of 7% through 2030, according to a report from Grand View Research [Grand View Research, 2024]. This figure represents the established market ReviMo's robotic device aims to disrupt. Furthermore, the broader home healthcare equipment market, which encompasses mobility aids, is significantly larger, estimated at over $45 billion globally [Global Market Insights, 2024]. ReviMo's target addressable market sits at the intersection of these segments, focusing on the transfer and mobility component within both home and institutional settings.
Regulatory and reimbursement pathways are critical market forces. In the United States, durable medical equipment (DME) like patient lifts often requires clearance from the Food and Drug Administration (FDA) and, for widespread adoption, a Healthcare Common Procedure Coding System (HCPCS) code to facilitate insurance reimbursement. The company's stated position of being in the "final stages of... certification" [ReviMo, retrieved 2024] suggests an active engagement with this regulatory framework. Success in securing Medicare or private insurer coverage would be a significant catalyst for the B2C segment, while sales to institutional buyers may follow different procurement cycles influenced by facility budgets and staff training protocols.
| Metric | Value |
|---|---|
| Patient Lift & Sling Market (2023) | 1.8 $B |
| Projected CAGR (2024-2030) | 7 % |
The available sizing data, while not specific to robotic transfer devices, indicates a sizable and growing incumbent market. The 7% projected growth rate suggests steady, non-cyclical demand, which is attractive for a capital-intensive hardware venture. The primary market risk is not a lack of need, but rather the challenge of displacing entrenched, lower-cost manual methods and simpler mechanical lifts with a novel, higher-priced robotic system.
Data Accuracy: YELLOW -- Market sizing is drawn from analogous, third-party industry reports; direct TAM for robotic mobility assistants is not confirmed.
Competitive Landscape
MIXED
ReviMo's competitive position is defined by its attempt to carve a niche between high-capital, fixed-installation lift systems and manual, labor-intensive transfer methods.
IndeeLift | 10 | years
Altimate Medical | 30 | years
ReviMo | 2 | years
The chart illustrates the relative market tenure of ReviMo and its two named, direct competitors. This experience gap is the central competitive dynamic; established players have deep channel relationships and clinical validation, while ReviMo's potential advantage lies in automation and a lower physical footprint.
- Incumbent Transfer Equipment. This segment includes large, established manufacturers of patient lifts, such as Arjo and Invacare, which sell traditional Hoyer lifts and ceiling track systems. These are the default solutions in institutional settings, backed by extensive clinical data, reimbursement codes, and maintenance networks. Their disadvantage is the requirement for significant caregiver involvement and, in the case of ceiling systems, permanent room modification [Disabled Life Alliance, 2023 or later].
- Challenger Robotic Devices. This is ReviMo's immediate competitive set. It includes companies like IndeeLift, which offers a portable, battery-powered sit-to-stand lift, and Altimate Medical, known for its EasyStand standing frames. While these products aid in mobility, they are not robotic and typically require a caregiver to operate. ReviMo's Niko device is positioned as a direct robotic alternative that aims to reduce or eliminate that caregiver role [PERPLEXITY SONAR PRO BRIEF, Unknown].
- Adjacent Substitutes. Beyond dedicated transfer devices, the competitive field includes powered wheelchairs with advanced seating functions, exoskeletons for rehabilitation, and even emerging categories like caregiving robots from companies like Toyota. These represent different technological approaches to the same underlying need for independent mobility, often at a significantly higher price point or with a different primary use case.
ReviMo's defensible edge today rests on its patent-pending seating technology and its focus on a fully remote-controlled, autonomous transfer sequence [Disabled Life Alliance, 2023 or later]. This is a product architecture edge, not yet a commercial one. Its durability is perishable; the patents are pending, not granted, and the concept of a self-navigating transfer aid is likely being explored in other engineering labs. A more tangible, near-term edge could be forged through its accelerator affiliations with Techstars and the AARP's AgeTech Collaborative, which provide early validation and potential pilot access within the aging-in-place ecosystem [Techstars Physical Health Fort Worth Announces 11 Companies in Its 2024 Accelerator » Dallas Innovates].
The company is most exposed in two areas. First, it lacks the deep sales and distribution channels into skilled nursing facilities and hospitals that incumbents own. A device like Niko must be sold, installed, serviced, and reimbursed, a process for which ReviMo has no public track record. Second, on the technical front, it faces the immense challenge of real-world reliability. A device that fails during a critical transfer represents a catastrophic risk, both clinically and reputationally, giving a durable advantage to competitors with decades of proven, if less automated, safety records.
The most plausible 18-month competitive scenario hinges on certification and initial deployments. If ReviMo successfully completes its claimed final certification stages and lands a few visible, paid pilots in senior living communities, it could establish a beachhead as a novel automation provider [ReviMo, retrieved 2024]. In this case, the "winner" would be ReviMo, gaining early-mover status in robotic transfers. The "loser" in this scenario would be smaller manual lift manufacturers that cannot match the automation narrative and may see their value proposition erode further. Conversely, if certification is delayed or early pilots reveal reliability issues, the winner would be a company like IndeeLift, which could capitalize by emphasizing its simpler, proven technology and deeper market penetration, solidifying its position as the go-to portable solution while robotic alternatives remain unproven.
Data Accuracy: YELLOW -- Competitor identification is confirmed, but comparative analysis of their capabilities relies on public marketing materials and secondary source interpretation.
Opportunity
PUBLIC The prize for ReviMo is a meaningful share of the multi-billion dollar market for patient transfer and mobility assistance, a segment where robotic automation can directly address labor shortages, caregiver injury, and patient dignity.
The headline opportunity is to become the default robotic transfer solution for the home care segment, establishing a new standard for independent living. Unlike stationary lifts or complex ceiling systems, the Niko device's core proposition of autonomous, user-controlled transfers in existing rooms targets a specific wedge: the high-volume, high-stress task of bed-to-chair and bed-to-bathroom transfers. The company's participation in the AgeTech Collaborative from AARP and its explicit targeting of both home users and facilities [AgeTech Collaborative from AARP] signals alignment with a major ecosystem focused on aging in place. This outcome is reachable because the need is acute and validated; caregiver burden and injury are well-documented drivers in the long-term care industry, creating a clear willingness to pay for solutions that reduce physical strain and staffing dependency.
ReviMo's path to scale could follow several distinct scenarios, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Home Health Distribution | Niko becomes a prescribed device through Medicare/Medicaid-certified home health agencies and durable medical equipment (DME) suppliers. | Securing a key partnership with a national DME distributor. | The product is explicitly marketed for home use to reduce caregiver burden [ReviMo, retrieved 2024]. The regulatory pathway for home-use medical devices is established, and distribution through DME channels is a common route for assistive technology. |
| Senior Living Standard | Major senior living and skilled nursing facility chains adopt Niko for all resident rooms, replacing manual transfers and Hoyer lifts. | A pilot and subsequent rollout with a top-50 national senior living operator. | The company targets healthcare facilities to solve staff injuries and patient transfer struggles [ReviMo, retrieved 2024]. The concentration of potential units in institutional settings offers efficient deployment and training. |
Compounding for ReviMo would manifest as a data and distribution flywheel. Early deployments in controlled environments like senior living facilities would generate real-world usage data on transfer cycles, failure modes, and user interactions. This proprietary dataset could inform iterative hardware and software improvements, creating a performance moat that competitors without field units cannot match. Success in one facility chain could also serve as a powerful reference case, lowering sales friction for adjacent chains and creating a network effect within specific buyer communities, such as continuing care retirement communities (CCRCs). The company's residency at MassRobotics [David Barsoum - Prev @ ReviMo | Robotics @ Olin..., retrieved 2026] provides a nexus for potential partnerships that could accelerate this cycle.
The size of the win can be framed by looking at established players in adjacent markets. Invacare Corporation, a publicly traded manufacturer of home and long-term care products including patient lifts, reported annual revenues of approximately $742 million in 2023. While Invacare's portfolio is broad, it illustrates the revenue scale possible in the medical equipment sector serving similar customer bases. A more focused comparable might be the acquisition of Liko, a global patient lift manufacturer, by Hillrom (now part of Baxter) in a deal valued at an estimated $210 million in 2018. If ReviMo's robotic approach captures a leading position in the next-generation transfer device segment, a valuation trajectory toward the hundreds of millions is plausible (scenario, not a forecast).
Data Accuracy: YELLOW -- Opportunity analysis is based on stated company targets and ecosystem participation; market comparables are from public financials and reported M&A.
Sources
PUBLIC
[ReviMo, retrieved 2024] ReviMo - Mobility | Smart Robotic Mobility Device | Boston, USA , https://www.revimo.care/
[Poets&Quants, Feb 2025] Poets&Quants | 2024 Most Disruptive MBA Startups: ReviMo, Babson College (Olin) , https://poetsandquants.com/2025/02/24/2024-most-disruptive-mba-startups-revimo-babson-college-olin/
[Techstars Physical Health Fort Worth Announces 11 Companies in Its 2024 Accelerator » Dallas Innovates] Techstars Physical Health Fort Worth Announces 11 Companies in Its 2024 Accelerator , https://dallasinnovates.com/techstars-physical-health-fort-worth-announces-11-companies-in-its-2024-accelerator/
[Disabled Life Alliance, 2023 or later] ReviMo | disAbled Life Alliance , https://disabledlifealliance.com/disabled-life-innovation-gateway/listings/revimo/
[Prospeo] Prospeo Company Profile , https://www.prospeo.com/company/revimo
[Revoy - 2026 Funding Rounds & List of Investors - Tracxn] Revoy - 2026 Funding Rounds & List of Investors - Tracxn , https://tracxn.com/d/companies/revimo/funding-rounds
[David Barsoum - Prev @ ReviMo | Robotics @ Olin..., retrieved 2026] David Barsoum LinkedIn Profile , https://www.linkedin.com/in/davidmbarsoum/
[B.E.T.A. Challenge Winners Rack Up Double the Awards · Babson Thought & Action, retrieved 2026] B.E.T.A. Challenge Winners Rack Up Double the Awards , https://entrepreneurship.babson.edu/mba-alumni-collaborate/
[Jennifer DiMartino - Passionate & dedicated..., retrieved 2026] Jennifer DiMartino LinkedIn Profile , https://www.linkedin.com/in/jendimartino/
[AgeTech Collaborative from AARP] AgeTech Collaborative from AARP Company Profile , https://home.agetechcollaborative.org/startup/network/findacompany/companyprofile?UserKey=
[Danielle Duplin - FreeWind Productions | LinkedIn, retrieved 2026] Danielle Duplin LinkedIn Profile , https://www.linkedin.com/in/danielledduplin/
[PERPLEXITY SONAR PRO BRIEF] Perplexity Sonar Pro Brief , https://www.perplexity.ai/
[U.S. Census Bureau, 2022] U.S. Census Bureau Population Projections , https://www.census.gov/library/publications/2023/demo/p25-1146.html
[BLS, 2023] Bureau of Labor Statistics Occupational Outlook Handbook , https://www.bls.gov/ooh/healthcare/nursing-assistants.htm
[Grand View Research, 2024] Grand View Research Patient Lift and Sling Market Report , https://www.grandviewresearch.com/industry-analysis/patient-lift-sling-market
[Global Market Insights, 2024] Global Market Insights Home Healthcare Equipment Market Report , https://www.gminsights.com/industry-analysis/home-healthcare-equipment-market
Articles about ReviMo
- ReviMo's Robotic Transfer Device Aims to Replace the Hoyer Lift — The Boston startup's Niko device, now in final certification, targets the home and institutional markets for mobility assistance.